What is the current stock price of ArriVent BioPharma, Inc. Common Stock (AVBP)?

As of the latest market data, ArriVent BioPharma, Inc. Common Stock (AVBP) is trading at $25.46. The stock has seen a loss of -6.57% today.

Does ArriVent BioPharma, Inc. Common Stock (AVBP) pay a dividend?

Based on current data, ArriVent BioPharma, Inc. Common Stock does not have a confirmed active dividend policy.

What is the market cap of ArriVent BioPharma, Inc. Common Stock?

The current market capitalization of ArriVent BioPharma, Inc. Common Stock (AVBP) is approximately unavailable.

AVBP

ArriVent BioPharma, Inc. Common Stock·Healthcare

25.46

6.569%(−1.79)

Market Closed

27.78

9.112%(+2.32)

After Hours

Last Updated: — ET

52W L: $16.1052W H: $27.75

AVBP NEWS

zacks.com

5d ago

Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet

The mean of analysts' price targets for ArriVent BioPharma, Inc. (AVBP) points to a 72.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

zacks.com

Mar 26

Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year?

Here is how ArriVent BioPharma, Inc. (AVBP) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.

seekingalpha.com

Mar 24

ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib

The readout for Firmonertinib has moved to mid-2026, which may reflect slower event accumulation and potentially longer progression-free survival compared with the current standard of care. If the drug delivers PFS above ~10 months with statistical significance, Firmonertinib could capture meaningful market share thanks to its oral monotherapy profile and potentially better safety relative to Rybrevant. With $312 million cash (runway to Q3 2027), the valuation appears asymmetric relative. We remain buyers.

globenewswire.com

Mar 17

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting

NEWTOWN SQUARE, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced two poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California April 17-22.

zacks.com

Mar 10

Wall Street Analysts See a 70.37% Upside in ArriVent BioPharma, Inc. (AVBP): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 70.4% in ArriVent BioPharma, Inc. (AVBP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

zacks.com

Mar 10

Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year?

Here is how ArriVent BioPharma, Inc. (AVBP) and Ocugen (OCGN) have performed compared to their sector so far this year.

Company Profile

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2024-01-26

Beta

0.86

Websitewww.arrivent.com↗